IRIS
RISITANO, ANTONIO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.228
AS - Asia 1.352
EU - Europa 1.089
AF - Africa 37
SA - Sud America 27
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4.736
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.107
SG - Singapore 578
CN - Cina 351
IT - Italia 347
HK - Hong Kong 297
RU - Federazione Russa 197
FI - Finlandia 118
CA - Canada 113
NL - Olanda 112
IE - Irlanda 89
VN - Vietnam 84
DE - Germania 60
GB - Regno Unito 35
UA - Ucraina 34
CI - Costa d'Avorio 32
FR - Francia 27
SE - Svezia 27
IN - India 19
BR - Brasile 18
JP - Giappone 10
LT - Lituania 8
MX - Messico 8
AT - Austria 7
BE - Belgio 7
ES - Italia 5
AR - Argentina 4
PS - Palestinian Territory 4
EU - Europa 3
NG - Nigeria 3
VE - Venezuela 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
EG - Egitto 2
GR - Grecia 2
ID - Indonesia 2
RO - Romania 2
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
KR - Corea 1
LB - Libano 1
LU - Lussemburgo 1
ME - Montenegro 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PL - Polonia 1
SI - Slovenia 1
Totale 4.736
Salva come PNG Salva come JPEG
Città #
Singapore 397
Chandler 346
Hong Kong 295
Millbury 171
Santa Clara 144
Princeton 133
Nanjing 125
Boston 122
Des Moines 116
Amsterdam 101
Ottawa 100
Dong Ket 84
Naples 80
Napoli 70
Ashburn 65
Beijing 55
Lawrence 46
Wilmington 41
Jacksonville 36
Shenyang 36
Nanchang 29
Seattle 29
Hebei 26
Tianjin 24
Jiaxing 18
Helsinki 17
Milan 16
Ann Arbor 15
Falkenstein 15
Redwood City 13
Woodbridge 13
Changsha 11
Nuremberg 9
Rome 9
New York 8
Norwalk 8
Canterbury 7
Latronico 7
Mexico City 7
Mountain View 7
Brussels 6
London 6
Dalmine 5
Montreal 5
Crispano 4
Frankfurt am Main 4
Hyderabad 4
Kronberg 4
Madrid 4
Pune 4
Stockholm 4
Toronto 4
Boardman 3
Columbus 3
Dublin 3
Engelskirchen 3
Fairfield 3
Falls Church 3
Fremont 3
Hamilton 3
Indiana 3
Kunming 3
Laferrere 3
Lagos 3
Los Angeles 3
Munich 3
Nocera Inferiore 3
Oleggio 3
San Mateo 3
Tampa 3
Taranto 3
Tokyo 3
Utrecht 3
Vienna 3
Bergamo 2
Brno 2
Bucharest 2
Canegrate 2
Catania 2
Cesano Boscone 2
Council Bluffs 2
Dallas 2
Edinburgh 2
Graulhet 2
Guangzhou 2
Gurgaon 2
Lappeenranta 2
Montegiorgio 2
Nagareyama 2
New Delhi 2
Padova 2
Palermo 2
Pozzuoli 2
Redmond 2
Saint Petersburg 2
Springfield 2
Sterling 2
São Paulo 2
Thessaloniki 2
Tulkarm 2
Totale 3.023
Salva come PNG Salva come JPEG
Nome #
Narrative Based Medicine as a tool for needs assessment of patients undergoing hematopoietic stem cell transplantation 65
Eltrombopag for post-transplant cytopenias due to poor graft function 62
(Auto-)immune signature in aplastic anemia 61
Paroxysmal Nocturnal Hemoglobinuria: significant association with specific HLA-A, B, C and DR alleles in Italian patients 58
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey 58
LONG-TERM FOLLOW UP OF ALENTUZUMAB-BASED IMMUNOSUPPRESSION FOR THE TREATMENT OF IMMUNE-MEDIATED BONE MARROW FAILURE SYNDROMES 56
Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. 52
CIRCULATING MEGAKARYOCYTE-DERIVED CELLS DETECTED BY FLOW CYTOMETRY AS MARKER OF AGGRESSIVE NEOPLASM OF MEGAKARYOCYTIC LINEAGE IN ACUTE MEGAKARYOBLASTIC LEUKEMIA AND ALLIED MALIGNANCIES PRESENTING AS PRIMARY MYELOFIBROSIS 51
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 51
Long-lasting bone damage detected by dual-energy x-ray absorptiometry,phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation 49
ALEMTUZUMAB FOR APLASTIC ANEMIA AND RELATED IMMUNE-MEDIATED BONE MARROW FAILURES: LONG-TERM FOLLOW UP OF A PILOT STUDY 49
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future 49
Killer Immunoglobulin-like Receptors (KIR) and their HLA-ligands in Italian Paroxysmal Nocturnal Haemoglobinuria (PNH) patients 48
PEGYLATED-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE 48
Antilymphocyte globulin for prevention of chronic graft-versus-host disease 48
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 47
PEG-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : A SINGLE-CENTRE EXPERIENCE 47
Acute immune toxicity during anti-thymocyte globulin: That's CARPA! 47
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for proximal complement inhibition? A position paper from the SAAWP of the EBMT 47
New perspectives on the use of nucleic acids in pharmacological applications: inhibitory action of extracellular self-DNA in biological systems 45
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 44
Twenty years of the Italian Fanconi Anemia Registry: Where we stand and what remains to be learned 43
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: A retrospective analysis 43
Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab). 42
Eculizumab treatment modifies the immune profile of PNH patients. 41
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria 41
Retroperitoneal extramedullary relapse after blinatumomab in acute lymphoblastic leukemia failing haplo-identical bone marrow transplantation. 41
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 41
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. 40
CHRONIC GRAFT Vs HOST DISEASE OF THE GENITAL TRACT: DIAGNOSIS, CLINICAL IMPACT AND MANAGEMENT FROM SURVEILLANCE PROGRAM IN A PRELIMINARY COHORT 40
Network references for rare diseases: state of the art for the paroxysmal nocturnal hemoglobinuria 40
A pilot study of the recombinant soluble human tumor necrosis factor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. 39
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia 38
XM02 PLUS CHEMOTHERAPY IS SAFE AND EFFECTIVE IN STEM CELL MOBILIZATION FOR PATIENTS CANDIDATED TO AUTOLOGOUS STEM CELL TRANSPLANTATION 38
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High Dose Cyclophosphamide 38
Aplastic anemia: immunosuppression. Current challenges and future goals in immunosuppression for aplastic anemia. 37
Epidemiology of Acquired Bone Marrow Failure 37
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study 37
Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule 37
Transplant results in adults with Fanconi anaemia 36
THIOTEPA AND MELPHALAN AS NEW CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE LYELOMA 36
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions 36
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 35
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 35
Aplastic anemia: immunosuppressive therapy in 2010. 35
Therapeutic complement modulation for hematological diseases: Where we stand and where we are going 35
Oral dysplastic complications after HSCT: Single case series of multidisciplinary evaluation of 80 patients 35
Role of the Urokinase Receptor (uPaR) in the cross-talk of hematopoietic Stem Cells with the bone marrow environment 34
Application of the molecular analsysis of the T –cell receptor repertoire in the study of immune-mediated hematologic disease. 34
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies 34
Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis 34
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anemia and single-lineage marrow failure: a pilot study and a survey from EBMT WPSAA. 33
Stem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantation 33
Long lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant 32
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010 Meeting Report. 32
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group 32
Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group 32
Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. 31
Advances in understanding the pathogenesis of acquired aplastic anaemia 31
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial 30
Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein (PrPc). 30
Allogeneic stem cell transplantation for acquired pure red cell aplasia 30
Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria 29
Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties 29
Immune insights into AA 28
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria 27
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation 26
Aplastic anemia: management of adult patients. 26
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going 26
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 26
Stem cell transplantation in severe congenital neutropenia: An analysis from the European Society for Blood and Marrow Transplantation 26
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 26
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 25
Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. 25
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. 25
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 25
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the gruppo italiano trapianto midollo osseo (GITMO) 25
Small-molecule factor D inhibitors targeting the alternative complement pathway 25
Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party 25
Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita 25
Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab 25
Safety and Efficacy of the TerminalC5 Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. 24
Use of eltrombopag in aplastic anemia in Europe 24
Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria 24
Paroxysmal Nocturnal Hemoglobinuria: The Future Of Complement-Based Therapies 24
Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. 23
Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. 23
T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. 23
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. 23
Dissecting complement blockade for clinic use 23
Complement inhibition for paroxysmal nocturnal hemoglobinuria: Where we stand and where we are going 23
Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria 23
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria 23
CD34+ cells from Paroxysmal Nocturnal Hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrPc). 22
Rabbit ATG for aplastic anaemia treatment: a backward step? 22
Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups. 22
Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant 22
Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria 22
Clonal non-malignant hematological disorders: unraveling molecular pathogenic mechanisms to develop novel targeted therapeutics 22
Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls 21
Totale 3.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020153 0 0 0 0 0 0 0 4 1 32 66 50
2020/2021303 52 14 13 9 36 25 12 3 25 2 23 89
2021/2022816 2 1 2 1 3 26 7 42 96 42 151 443
2022/2023911 191 79 18 33 106 97 9 107 128 90 44 9
2023/2024601 10 107 108 26 27 43 8 52 8 9 153 50
2024/20251.475 246 241 15 37 60 153 506 217 0 0 0 0
Totale 4.982